KMDA.TA - Kamada Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
1,805.00
+5.00 (+0.28%)
As of 1:47PM IST. Market open.
Stock chart is not supported by your current browser
Previous Close1,800.00
Open1,775.00
Bid1,800.00 x 346500
Ask1,805.00 x 57900
Day's Range1,775.00 - 1,808.00
52 Week Range1,505.00 - 2,320.00
Volume15,034
Avg. Volume37,157
Market Cap727.17M
Beta (3Y Monthly)0.55
PE Ratio (TTM)7,520.83
EPS (TTM)0.24
Earnings DateFeb 1, 2019 - Feb 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates
    Zackslast month

    Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates

    Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Kamada: 3Q Earnings Snapshot

    The Rehovot, Israel-based company said it had a loss of 6 cents per share. Losses, adjusted for stock option expense, came to 5 cents per share. The biopharmaceutical posted revenue of $15 million in the ...

  • GlobeNewswirelast month

    Kamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12

    REHOVOT, Israel, Nov. 05, 2018 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.

  • GlobeNewswire2 months ago

    Kamada Announces Appointment of Life Sciences Industry Executive Eitan Kyiet as Vice President of Business Development

    Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Eitan Kyiet as Vice President of Business Development.  Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry. Mr. Kyiet will report directly to Amir London, Kamada’s Chief Executive Officer.

  • GlobeNewswire3 months ago

    Kamada to Present Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference

    REHOVOT, Israel, Sept. 25, 2018-- Kamada Ltd., a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor ...

  • The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants

    The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants

  • Kamada (KMDA) Surpasses Q2 Earnings and Revenue Estimates
    Zacks4 months ago

    Kamada (KMDA) Surpasses Q2 Earnings and Revenue Estimates

    Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Kamada: 2Q Earnings Snapshot

    On a per-share basis, the Rehovot, Israel-based company said it had profit of 14 cents. The biopharmaceutical posted revenue of $33.8 million in the period. Kamada shares have climbed 22 percent since ...

  • Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?
    Zacks6 months ago

    Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

    Is (KMDA) Outperforming Other Medical Stocks This Year?

  • Associated Press7 months ago

    Kamada: 1Q Earnings Snapshot

    On a per-share basis, the Ness Ziona, Israel-based company said it had profit of 3 cents. The biopharmaceutical posted revenue of $17.4 million in the period. Kamada expects full-year revenue in the range ...

  • Business Wire7 months ago

    Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin ) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

    Kedrion Biopharma and Kamada Ltd. (KMDA) (KMDA.TA), two leading human-derived protein therapeutics companies, announced today that KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches. KEDRAB, a human rabies immune globulin (HRIG), received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two HRIG therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus. KEDRAB, the newest entry into the $100 million plus U.S. rabies market, represents another safe, effective treatment choice for healthcare professionals seeking an alternative to currently available HRIGs.

  • Associated Press10 months ago

    Kamada posts 4Q profit

    On a per-share basis, the Ness Ziona, Israel-based company said it had net income of 16 cents. The biopharmaceutical posted revenue of $35.7 million in the period. For the year, the company reported net ...